Annual Report
Annual Report
Foreword
'Though the COVID-19 pandemic continued to take a devastating toll in 2021, we advanced 50 projects in our research and development portfolio, including multiple new chemical entities, delivered new treatments, and forged new alliances for innovation.'
Dr Marie-Paule Kieny, Chair of the Board of Directors &
Dr Bernard Pécoul, Executive Director
2021 in numbers
41 R&D projects and an additional
9 projects in the access phase
27 clinical trials in 8 disease areas at 88 sites in 28 countries
80% of all R&D partner FTEs* are based in low-and-middle-income countries
*Staff in full-time equivalents
EUR 66 M in annual expenditure,
89% of which on our social mission
Our cross-cutting commitments
DNDi’s 2021-2028 strategic plan charts our path to deliver 25 new treatments for neglected patients in our first 25 years. Learn more about the strategic imperatives shaping our work to end the neglect.
Features
Take a tour of highlights of the year from our teams and partners in Africa, Asia, and Latin America.
DNDi’s Data Management and Biostatistics Centre in Nairobi, Kenya has helped to maximize clinical research capacity in Africa since 2004.
Leveraging our experience bolstering South-South collaboration for hepatitis C R&D, we are now joining essential government, science, and industry partners across LMICs to find a safe, effective, and affordable treatment for dengue fever.
Since the start of intensified VL detection and treatment activities in India, VL cases have plummeted by 98%, from 77,100 registered cases in 1992 to just 1,275 in 2021. However, the ‘last mile’ of India’s push toward VL elimination presents unique challenges, as will sustaining elimination, once achieved.
At the end of 2021, DNDi, the University of São Paulo, and Medicines for Malaria Venture (MMV) joined forces to identify and develop new lead molecules targeting SARS-CoV-2 that can be advanced to clinical trials for new safe, effective, and affordable antiviral treatments for COVID-19.
Health workers often lack access to the information they need to identify and care for people with Chagas. To help overcome this barrier, DNDi launched the mobile application iChagas in 2021, developed with partners across the region.
DNDi research worldwide
Early-stage research and clinical development in 2021
in 8 disease areas
clinical studies
Active clinical sites
- Sleeping sickness
- Leishmaniasis
- Chagas disease
- Filaria: River blindness
- Mycetoma
- HIV
- Hepatitis C
- COVID-19
EARLY-STAGE RESEARCH SITES
(Drug discovery and pre-clinical development)RESEARCH PLATFORMS AND NETWORKS
Map boundaries and borders do not reflect any position by DNDi on their legal status
Our progress in 2021
Sleeping sickness
Delivering breakthrough treatments and expediting access for sustained elimination
Hepatitis C
Accelerating access to affordable treatments and supporting global elimination efforts
From bench to bedside
DNDi research & development portfolio
Acting as a ‘conductor of a virtual orchestra’, we collaborate with research partners around the world at all stages of the R&D process. Our R&D portfolio includes 49 projects and 20 new chemical entities for 9 disease areas.
Photo credits: Brent Stirton/Getty Images; Manon Voland-DNDi; Kishore Pandit-DNDi; Sydelle Willow Smith-EDCTP; Vinicius Berger-DNDi; DeepMind; Karin Schermbrucker-DNDi; Black Visuals-DNDi; Manis Gupta-DNDi; Ana Ferreira-DNDi; Emmanuel Museruka-DNDi; Ley Uwera-DNDi; Lameck Ododo-DNDi; Xavier Vahed-DNDi; Abang Amirrul Hadi-DNDi; Maneesh Agnihotri-DNDi
A word of thanks
DNDi has now delivered 12 new treatments for six neglected diseases.
Every contribution is essential to advancing DNDi’s mission and goals. We are deeply grateful to our donors and partners for their support in 2021.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
